See more : Jia Yao Holdings Limited (1626.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Immuno-Biological Laboratories Co., Ltd. (4570.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immuno-Biological Laboratories Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Costar Technologies, Inc. (CSTI) Income Statement Analysis – Financial Results
- Crédit Agricole S.A. (CRARY) Income Statement Analysis – Financial Results
- Betterware de México, S.A.P.I. de C.V. (BWMX) Income Statement Analysis – Financial Results
- IMBDX Inc (461030.KQ) Income Statement Analysis – Financial Results
- Taiba Investments Co. (4090.SR) Income Statement Analysis – Financial Results
Immuno-Biological Laboratories Co., Ltd. (4570.T)
About Immuno-Biological Laboratories Co., Ltd.
Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 816.70M | 794.62M | 647.58M | 602.75M | 576.00M |
| Cost of Revenue | 299.41M | 267.91M | 270.88M | 255.89M | 360.00M |
| Gross Profit | 517.29M | 526.71M | 376.70M | 346.86M | 216.00M |
| Gross Profit Ratio | 63.34% | 66.28% | 58.17% | 57.55% | 37.50% |
| Research & Development | 129.98M | 179.66M | 188.59M | 267.11M | 318.00M |
| General & Administrative | 7.42M | 8.75M | 4.76M | 8.86M | 38.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 456.00M |
| SG&A | 7.42M | 8.75M | 4.76M | 8.86M | 494.00M |
| Other Expenses | 275.59M | -7.00M | 5.55M | 16.02M | 0.00 |
| Operating Expenses | 412.99M | 468.33M | 498.91M | 587.83M | 875.00M |
| Cost & Expenses | 712.40M | 736.24M | 769.79M | 843.73M | 1.24B |
| Interest Income | 93.00K | 1.36M | 487.00K | 151.00K | 86.00K |
| Interest Expense | 1.13M | 1.07M | 641.00K | 749.00K | 932.00K |
| Depreciation & Amortization | 2.33M | -204.93M | -143.70M | -69.93M | 596.00M |
| EBITDA | 128.11M | -332.00M | -249.50M | -309.88M | -63.00M |
| EBITDA Ratio | 15.69% | -18.44% | -41.06% | -51.58% | -10.94% |
| Operating Income | 104.30M | 58.37M | -122.22M | -240.98M | -596.00M |
| Operating Income Ratio | 12.77% | 7.35% | -18.87% | -39.98% | -103.47% |
| Total Other Income/Expenses | 20.35M | -338.98M | -127.92M | -69.65M | -62.69M |
| Income Before Tax | 124.64M | -280.61M | -250.14M | -310.63M | -659.00M |
| Income Before Tax Ratio | 15.26% | -35.31% | -38.63% | -51.54% | -114.41% |
| Income Tax Expense | -62.05M | 9.12M | 8.63M | 8.20M | 9.00M |
| Net Income | 186.69M | -289.73M | -258.77M | -318.83M | -668.00M |
| Net Income Ratio | 22.86% | -36.46% | -39.96% | -52.90% | -115.97% |
| EPS | 20.05 | -31.11 | -27.78 | -34.23 | -75.99 |
| EPS Diluted | 20.05 | -31.11 | -27.78 | -34.23 | -75.99 |
| Weighted Avg Shares Out | 9.31M | 9.31M | 9.31M | 9.31M | 8.79M |
| Weighted Avg Shares Out (Dil) | 9.31M | 9.31M | 9.31M | 9.31M | 8.79M |
Source: https://incomestatements.info
Category: Stock Reports